Oncology

Visit MyAstraZeneca for more information on our therapeutic areas.

Our ambition is to eliminate cancer as a cause of death. To transform oncology care in Switzerland, we advance early detection, precision medicine, and targeted therapies across breast, lung, gastrointestinal, gynaecological, genitourinary, and haematological cancers. By investigating novel biologic and small-molecule combinations, our innovative treatments directly attack tumours and leverage immuno-oncology to stimulate the body's natural defences.

Our focus areas

Lung cancer

Lung cancer remains a leading cause of cancer mortality.1 We are committed to early detection programs, personalised treatment pathways, and scientific research to improve survival rates.

Breast cancer

Our ambition is to improve outcomes for people living with breast cancer across all stages and subtypes. In Switzerland, we advance precision medicine and support early screening to ensure timely diagnosis and personalised treatment.

Gastrointestinal cancers

Gastrointestinal cancers remain a significant healthcare challenge in Switzerland.2 We are advancing research into early-detection biomarkers, immunotherapies, and targeted therapies.

Gynaecological cancers

Ovarian and endometrial cancers remain complex – early detection and prevention are critical.3,4 With precision medicine and immunotherapy, we work to transform care and improve survival for women across Switzerland.

Genitourinary cancers

We are committed to advancing science to better understand the drivers of prostate and bladder cancer, enabling more targeted therapies that improve outcomes and quality of life for all patients.

Haematology cancers

At AstraZeneca, we apply deep scientific insights to transform haematological cancer care. We pioneer targeted therapies and novel combination strategies to improve patient outcomes across blood cancers, including leukaemia, lymphoma, and myeloma.

For more information on AstraZeneca’s therapeutic areas - including disease risks, symptoms, early diagnosis and treatment options - visit myastrazeneca.ch

Learn more here

References

  1. World Health Organisation. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. (accessed September 2026).
  2. Bundesamt für Statistik (BFS). Cancer Monitoring Switzerland. Neuerkrankungen Krebs. Available at: https://cancer-monitorage.bfs.admin.ch/de/vergleich/neuerkrankungen/ (accessed September 2026).
  3. Journal of Clinical Oncology. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Available at: https://ascopubs.org/doi/10.1200/JCO.2016.66.8178 (accessed September 2026).
  4. Arthur, R.S., Kabat, G.C., Kim, M.Y. et al. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study. Cancer Causes Control 30, 355–363 (2019). https://doi.org/10.1007/s10552-019-01139-5

Veeva ID: CH-13770
Date of preparation: October 2026